XENE Stock Forecast: Xenon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$37
−1.38% on the day

The 18 Wall Street analysts covering Xenon Pharmaceuticals, Inc. hold a median 12-month price target of $72 — +93.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 41 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$3.7B
Ticker Nerd rank
41/ 100
Median analyst target
$72
Analysts covering
18
Revenue$0.0
Operating income−$123.2M
Net income−$110.7M
Free cash flow−$95.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.5%
1M
+2.1%
YTD
−17.4%
1Y
−8.0%
From 52W high
−47.8%
From 52W low
+10.6%
$33
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Xenon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
41/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
87
Revisions
67
Value
65
Momentum
52
Quality
42
Issuance
37
Accruals
33
Growth
28

Volatility (87): The share price has been relatively steady.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XENE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XENE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80$90Jan 26Apr 26Jul 26Oct 26XENEHigh $90Median $72Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
17
Buy
1
Hold
0
Sell
$46
Low
$72
Median
$90
High

The green dot is the last close — the median target sits +93.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
17 Nov 2026JP MorganMaintainsOverweight$82 → $80
6 Oct 2026GuggenheimAssumesBuy$73
18 Sept 2026BairdMaintainsOutperform$97 → $90
18 Sept 2026Deutsche BankDowngradeHold$90 → $46
18 Sept 2026NeedhamMaintainsBuy$78 → $60
18 Sept 2026RBC CapitalMaintainsOutperform$81 → $70
18 Sept 2026WedbushMaintainsOutperform$71 → $55
18 Sept 2026Wells FargoMaintainsOverweight$69 → $64
7 Aug 2026RBC CapitalMaintainsOutperform$82 → $81
27 May 2026JP MorganMaintainsOverweight$80 → $82
12 May 2026JP MorganMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
16 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Deutsche BankMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Wells FargoMaintainsOverweight—
9 Mar 2026BairdMaintainsOutperform—
9 Mar 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XENE.

Market Radar

This page is one stock. Monday covers all of them.

XENE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XENE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Xenon Pharmaceuticals, Inc. returned −8.0% against +6.9% for the S&P 500, dividends included.

XENE vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26XENES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XENE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
492.2×

Cheaper than 1% of US stocks

Price / book
3.2×

Cheaper than 28% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−50.3%

Higher than 22% of US stocks

Return on assets
−32.2%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xenon Pharmaceuticals, Inc. has a market value of $3.7B and an enterprise value of $2.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$409.2M.

  • Diluted earnings per share, trailing twelve months: −$4.74.

  • Free cash flow in the twelve months to 30 June 2026: −$338.5M.

  • Shares outstanding: 96.8M.

  • Xenon Pharmaceuticals, Inc. employs 358 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

XENE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XENEXenon Pharmaceuticals, Inc.$3.7B41
TNGXTango Therapeutics, Inc.$3.5B23
TARSTarsus Pharmaceuticals, Inc.$3.6B72
RLAYRelay Therapeutics, Inc.$3.5B80
PBLSParabilis Medicines, Inc.$3.4B2
IRONDisc Medicine, Inc.$3.3B42
CRSPCRISPR Therapeutics AG$3.8B33

Take a look at XENE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XENE

What is the XENE stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Xenon Pharmaceuticals, Inc. have a median 12-month price target of $72, with estimates ranging from $46 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XENE stock a buy right now?

Of the 18 analysts covering Xenon Pharmaceuticals, Inc., 17 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenon Pharmaceuticals, Inc. 41 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XENE?

As at 21 Nov 2026, Xenon Pharmaceuticals, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (87 of 100).

Will XENE stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +93.0% from the last close, and Ticker Nerd's factor model ranks Xenon Pharmaceuticals, Inc. 41 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XENE stock forecast for 2030?

No analyst covering Xenon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XENE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $90 over the next 12 months.

How has XENE stock performed over the past year?

Xenon Pharmaceuticals, Inc. returned -8.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenon Pharmaceuticals, Inc. do?

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions.

Company

About Xenon Pharmaceuticals, Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions. Its current programs include late-stage and early-stage candidates aimed at focal seizures, primary generalized tonic-clonic seizures, major depressive disorder, bipolar depression, and pain. The company operates as a single reportable segment focused on discovering, developing, and delivering therapeutics for patients with high unmet medical needs. Headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals Inc. has an operating presence in North America and collaborates with clinical and research partners to advance its development programs.

CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. · 358 employees · Canada · https://www.xenon-pharma.com